Is deployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso
暂无分享,去创建一个
D. Cirillo | E. Tagliani | R. Alagna | F. Ouédraogo | S. Diandé | Adjima Combary | T. Saouadogo | L. Sawadogo
[1] D. Cirillo,et al. Applying a Standardized Approach to Strengthen Performances of GeneXpert Networks programme: lessons learned from Burkina Faso, 2019 , 2020, ERJ Open Research.
[2] C. Gilpin,et al. Tuberculosis Supranational Reference Laboratories: A Global Approach. , 2019, Clinics in chest medicine.
[3] D. Falzon,et al. Advances in clinical trial design for development of new TB treatments—Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam , 2019, PLoS medicine.
[4] P. Nahid,et al. Advances in clinical trial design for development of new TB treatments: A call for innovation , 2019, PLoS medicine.
[5] D. Cirillo,et al. ASAP-GxNet project in Burkina Faso: fulfil country capacity gaps to ensure efficient utilisation of GeneXpert instruments in tuberculosis care and cascade , 2019, ERJ Open Research.
[6] N. Arinaminpathy,et al. Supplement to: Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care Corresponding author: , 2019 .
[7] Alimuddin Zumla,et al. Improving access to multi-drug resistant tuberculosis diagnostic and health services for refugees and migrants , 2018, BMC Medicine.
[8] Zhi Zhen Qin,et al. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016 , 2018, Gates open research.
[9] M. Pai,et al. Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? , 2017, European Respiratory Journal.
[10] Madhukar Pai,et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? , 2016, European Respiratory Journal.
[11] Nimalan Arinaminpathy,et al. Understanding the incremental value of novel diagnostic tests for tuberculosis , 2015, Nature.
[12] N. Ford,et al. Strength of recommendations in WHO guidelines using GRADE was associated with uptake in national policy. , 2015, Journal of clinical epidemiology.
[13] C. Dye,et al. The impact of new tuberculosis diagnostics on transmission: why context matters. , 2012, Bulletin of the World Health Organization.
[14] I. Ruprah,et al. Does technical assistance matter? An impact evaluation approach to estimate its value added , 2009 .
[15] E. Rakotonirina,et al. [Factors associated with tuberculosis treatment non-compliance in Antananarivo city, Madagascar]. , 2009, Sante publique.
[16] R. Forsman,et al. The impact of the laboratory on disease management. , 2006, Disease management : DM.
[17] J. Henzen. Publisher's note , 1979, Brain Research.
[18] C. Dolea,et al. World Health Organization , 1949, International Organization.
[19] Adjima Combary,et al. Applying a Standardised Approach to Strengthen Performances of GeneXpert Networks (ASAP-GxNet) program: lessons learned from Burkina Faso, 2019 , 2020 .
[20] F. Klaus. Report 2020 , 2020 .
[21] L. Gabbasova,et al. Global tuberculosis report (2014) , 2014 .